amifostine anhydrous has been researched along with Prostatic Neoplasms in 17 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Early toxicity was overall low, proctitis being the most frequent side-effect (23." | 2.76 | Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. ( Giatromanolaki, A; Kalogeris, K; Koukourakis, MI; Kyrgias, G; Mavropoulou, S; Milioudis, N; Nassos, P; Panteliadou, M; Papadopoulou, A; Sivridis, E; Touloupidis, S, 2011) |
| "Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria." | 2.75 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010) |
| "Twenty-nine patients with localized prostate cancer were accrued." | 2.70 | Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. ( Ben-Josef, E; Biggar, S; Han, S; Kaplan, I; Kelly, L; Stamos, B; Tobi, M; Vargas, BJ, 2002) |
| "Grade 2 proctitis was noted in 18." | 1.38 | Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. ( Abatzoglou, I; Koukourakis, MI; Panteliadou, M; Papadopoulou, A; Sismanidou, K; Touloupidis, S, 2012) |
| "Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy." | 1.35 | Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. ( Albert, PS; Camphausen, K; Coleman, CN; Cooley-Zgela, T; Crouse, NS; Godette, D; Guion, P; Ménard, C; Sciuto, LC; Simone, NL; Singh, AK; Smith, S; Soule, BP, 2008) |
| "Twenty-nine patients with localized prostate cancer were accrued." | 1.31 | A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. ( Ben-Josef, E; Biggar, S; Bonner, HS; Han, S; Kaplan, I; Kelly, L; Prokop, S; Shaw, LM; Stamos, B; Tobi, M; Vargas, BJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsanos, KH | 1 |
| Briasoulis, E | 1 |
| Tsekeris, P | 1 |
| Batistatou, A | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Capizzello, A | 1 |
| Panelos, I | 1 |
| Karavasilis, V | 1 |
| Christodoulou, D | 1 |
| Tsianos, EV | 1 |
| Koukourakis, MI | 2 |
| Kyrgias, G | 1 |
| Papadopoulou, A | 2 |
| Panteliadou, M | 2 |
| Giatromanolaki, A | 1 |
| Sivridis, E | 1 |
| Mavropoulou, S | 1 |
| Kalogeris, K | 1 |
| Nassos, P | 1 |
| Milioudis, N | 1 |
| Touloupidis, S | 2 |
| Abatzoglou, I | 1 |
| Sismanidou, K | 1 |
| Ben-Josef, E | 4 |
| Han, S | 2 |
| Tobi, M | 2 |
| Shaw, LM | 2 |
| Bonner, HS | 2 |
| Vargas, BJ | 2 |
| Prokop, S | 1 |
| Stamos, B | 2 |
| Kelly, L | 2 |
| Biggar, S | 2 |
| Kaplan, I | 2 |
| Kouvaris, J | 1 |
| Kouloulias, V | 1 |
| Malas, E | 1 |
| Antypas, C | 2 |
| Kokakis, J | 1 |
| Michopoulos, S | 2 |
| Matsopoulos, G | 2 |
| Vlahos, L | 1 |
| Dziuk, T | 1 |
| Senzer, N | 1 |
| Linares, LA | 1 |
| Echols, D | 1 |
| Ménard, C | 4 |
| Camphausen, K | 4 |
| Muanza, T | 1 |
| Sears-Crouse, N | 1 |
| Smith, S | 4 |
| Coleman, CN | 4 |
| Mazeron, JJ | 1 |
| Kouloulias, VE | 1 |
| Kouvaris, JR | 1 |
| Pissakas, G | 1 |
| Mallas, E | 1 |
| Kokakis, JD | 1 |
| Mystakidou, K | 1 |
| Vlahos, LJ | 1 |
| Muanza, TM | 1 |
| Albert, PS | 3 |
| Godette, D | 2 |
| Crouse, NS | 3 |
| Cooley-Zgela, T | 3 |
| Sciuto, L | 1 |
| Singh, AK | 2 |
| Guion, P | 2 |
| Simone, NL | 2 |
| Godette, DJ | 1 |
| Sciuto, LC | 2 |
| Coleman, J | 1 |
| Pinto, P | 1 |
| Soule, BP | 1 |
| Kligerman, MM | 1 |
| Mesina, J | 1 |
| Shamsa, F | 1 |
| Porter, AT | 1 |
| Rubin, P | 1 |
| Salazar, O | 1 |
| Zagars, G | 1 |
| Constine, LS | 1 |
| Keys, H | 1 |
| Poulter, CA | 1 |
| Van Ess, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study[NCT00040365] | Phase 2 | 30 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EPIC bowel assessment is a 26 item short form evaluation that assess patient function and bother after prostate treatment. The Expanded Prostate Cancer Index Composite is a self assessment questionnaire designed to measure quality of life in patients with prostate cancer. The questionnaire is scored on a scale of 0-100 with higher scores correlated with higher function and quality of life. For this study, the Bowel Domain was analyzed alongside the RTOG acute and late gastrointestinal morbidity scores. For details re: EPIC, see http://www.med.umich.edu/urology/research/EPIC/EPIC-2.2002.pdf (NCT00040365)
Timeframe: 18 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Amifostine | 0.6 |
Proctoscopic scoring of mucosal change was performed according to a descriptive scale, described by Wachter et al, which assigns grades of mucosal congestion, telangiectasia, ulcerations, stricture, and necrosis. (NCT00040365)
Timeframe: 3 years
| Intervention | Participants (Number) |
|---|---|
| Amifostine | 30 |
Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00040365)
Timeframe: 3 years
| Intervention | Participants (Number) |
|---|---|
| Amifostine | 30 |
A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG (method and scoring of radiation morbidity, etc.) see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx (NCT00040365)
Timeframe: RTOG Acute was used on week 5 and 7
| Intervention | Percentage of Participants (Number) |
|---|---|
| Amifostine | 20.69 |
A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. Week 5, 7 were during treatment measuring acute toxicity. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx. (NCT00040365)
Timeframe: The late rectal toxicity has been assessed at 1, 3, 6, 12, 18, 24, 36, and 60 months after the completion of treatment.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Amifostine | 83.33 |
Radiation toxicity consists of the Radiation Therapy Oncology Group(RTOG)acute(within 90 days of treatment)and RTOG late(>90days after treatment). This scoring system assigns a toxicity grade (0-4) based on symptoms with 0 being the best outcome. The Expanded Prostate Cancer Index Composite(EPIC) questionnaire consists of 50 quality of life items divided into 4 domains, urinary, bowel, sexual and hormonal. Each independent domain renders a scoring of 0-100 with 100 being the best score. The EPIC and RTOG scores were correlated not combined. (NCT00040365)
Timeframe: Baseline, week 5, 7 , and months 1, 3, 6, 12, and 18
| Intervention | scores on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline bowel function | Baseline bowel bother | Week 5 bowel function | Week 5 bowel bother | Week 5 RTOG | Week 7 bowel function | Week 7 bowel bother | Week 7 RTOG | 1 month bowel function | 1 month bowel bother | 1 month RTOG | 3 month bowel function | 3 month bowel bother | 3 month RTOG | 6 month bowel function | 6 month bowel bother | 6 month RTOG | 12 month bowel function | 12 month bowel bother | 12 month RTOG | 18 month bowel function | 18 month bowel bother | 18 month RTOG | |
| Amifostine | 91.13 | 92.86 | 71.43 | 67.33 | 1.06 | 69.76 | 66.38 | 1.00 | 84.09 | 78.08 | 0.59 | 79.08 | 82.78 | 0.54 | 85.46 | 81.86 | 0.39 | 83.92 | 77.65 | 0.50 | 83.55 | 76.28 | 0.64 |
1 review available for amifostine anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
Topics: Amifostine; Brachytherapy; Clinical Trials as Topic; Feasibility Studies; Humans; Male; Prostatic Ne | 2003 |
9 trials available for amifostine anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U | 2010 |
Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Topics: Aged; Aged, 80 and over; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Feasibility Stud | 2011 |
Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Topics: Aged; Amifostine; Chi-Square Distribution; Data Interpretation, Statistical; Endometrial Neoplasms; | 2003 |
Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial.
Topics: Aged; Amifostine; Brachytherapy; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; | 2003 |
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Humans; Male; Middle Aged; Prostatic Neopl | 2003 |
Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Topics: Administration, Rectal; Amifostine; Female; Genital Neoplasms, Female; Humans; Injections, Subcutane | 2005 |
Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Topics: Aged; Amifostine; Chi-Square Distribution; Humans; Male; Middle Aged; Proctoscopy; Prostatic Neoplas | 2005 |
Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Topics: Adenocarcinoma; Administration, Rectal; Amifostine; Humans; Male; Prostatic Neoplasms; Radiation Dos | 2002 |
Systemic hemibody irradiation for overt and occult metastases.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1985 |
7 other studies available for amifostine anhydrous and Prostatic Neoplasms
| Article | Year |
|---|---|
Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Topics: Aged; Amifostine; Carcinoma; Cytoprotection; Diarrhea; Dysuria; Humans; Male; Middle Aged; Proctitis | 2012 |
A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
Topics: Adenocarcinoma; Administration, Topical; Amifostine; Analysis of Variance; Dose-Response Relationshi | 2002 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Topics: Administration, Rectal; Aged; Amifostine; Humans; Male; Pilot Projects; Proctitis; Prostatic Neoplas | 2006 |
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Dose-Response Relationship, Drug; Follow-U | 2008 |
Pions, protectors. Examples of a vigorous decade in radiotherapy.
Topics: Amifostine; Animals; Antineoplastic Agents; Drug Evaluation; Drug Therapy, Combination; Elementary P | 1982 |
Topical application of WR-2721 achieves high concentrations in the rectal wall.
Topics: Administration, Topical; Amifostine; Animals; Chromatography, High Pressure Liquid; Male; Prostate; | 1995 |